Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of Signaling Molecules pp 502–508Cite as

DARPP

  • Reference work entry

  • 55 Accesses

Synonyms

Darpp32; DARPP-32; Dopamine and adenosine 3′,5′-monophosphate-regulated phosphoprotein, 32 kDa; Dopamine and cAMP-regulated phosphoprotein; Dopamine- and cAMP-regulated phosphoprotein, Mr32 kDa; Ppp1r1b; Protein phosphatase 1 DARPP-32 inhibitor protein; Protein phosphatase 1, regulatory (inhibitor) subunit 1B

Historical Background

Recent studies using behavioral analysis of animal models suggest that alterations in critical intracellular signaling pathways have an important role in the pathophysiology and treatment of complex neuropsychiatric disorders. The hypothesis is that, if the vast majority of psychiatric medications exert their primary therapeutic actions in the first week of treatment, the therapeutic effects involve transcriptional changes initiated and maintained by critical intracellular signaling pathways.

The dopaminergic neurotransmission system has been the focus of much research throughout the last few decades, including psychiatric and neurological disorders,...

This is a preview of subscription content, log in via an institution.

References

  • Abdolahi A, Acosta G, Breslin FJ, Hemby SE, Lynch WJ. Incubation of nicotine seeking is associated with enhanced protein kinase A-regulated signaling of dopamine- and cAMP-regulated phosphoprotein of 32 kDa in the insular cortex. Eur J Neurosci. 2010;31(4):733–41.

    Article  PubMed  Google Scholar 

  • Albert KA, Hemmings HC, Jr, Adamo AI, et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiat. 2002;59(8):705–12.

    Article  PubMed  CAS  Google Scholar 

  • Andersson M, Usiello A, Borgkvist A, et al. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci. 2005;25(37):8432–8.

    Article  PubMed  CAS  Google Scholar 

  • Baracskay KL, Haroutunian V, Meador-Woodruff JH. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse. 2006;60(4):271–9.

    Article  PubMed  CAS  Google Scholar 

  • Beuten J, Ma JZ, Lou XY, Payne TJ, Li MD. Association analysis of the protein phosphatase 1 regulatory subunit 1B (PPP1R1B) gene with nicotine dependence in European- and African-American smokers. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(3):285–90.

    Article  PubMed  CAS  Google Scholar 

  • Bonoiu AC, Mahajan SD, Ding H, et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci USA. 2009;106(14):5546–50.

    Article  PubMed  CAS  Google Scholar 

  • Cardno AG, Holmans PA, Rees MI, et al. A genomewide linkage study of age at onset in schizophrenia. Am J Med Genet. 2001;105(5):439–45.

    Article  PubMed  CAS  Google Scholar 

  • Cash R, Raisman R, Ploska A, Agid Y. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson’s disease. J Neurochem. 1987;49(4):1075–83.

    Article  PubMed  CAS  Google Scholar 

  • Chen JC, Chen PC, Chiang YC. Molecular mechanisms of psychostimulant addiction. Chang Gung Med J. 2009;32(2):148–54.

    PubMed  Google Scholar 

  • Clinton SM, Ibrahim HM, Frey KA, et al. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiat. 2005;162(10):1859–71.

    Article  PubMed  Google Scholar 

  • Dick DM, Foroud T, Flury L, et al. Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet. 2003;73(1):107–14.

    Article  PubMed  CAS  Google Scholar 

  • Ehrman LA, Williams MT, Schaefer TL, et al. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav. 2006;5(7):540–51.

    Article  PubMed  CAS  Google Scholar 

  • Feldcamp LA, Souza RP, Romano-Silva M, et al. Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia. Schizophr Res. 2008;103(1–3):192–200.

    Article  PubMed  Google Scholar 

  • Fernandez-Ruiz J, Hernandez M, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16(3):e72–91.

    Article  PubMed  CAS  Google Scholar 

  • Fienberg AA, Greengard P. The DARPP-32 knockout mouse. Brain Res Brain Res Rev. 2000;31(2–3):313–9.

    Article  PubMed  CAS  Google Scholar 

  • Fienberg AA, Hiroi N, Mermelstein PG, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 1998;281(5378):838–42.

    Article  PubMed  CAS  Google Scholar 

  • Frank MJ, Moustafa AA, Haughey HM, Curran T, Hutchison KE. Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning. Proc Natl Acad Sci USA. 2007;104(41):16311–6.

    Article  PubMed  CAS  Google Scholar 

  • Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol. 2008;75(1):266–322.

    Article  PubMed  CAS  Google Scholar 

  • Girault JA, Hemmings HC, et al. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J Biol Chem. 1989;264(36):21748–59.

    PubMed  CAS  Google Scholar 

  • Heyser CJ, Fienberg AA, Greengard P, Gold LH. DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task. Brain Res. 2000;867(1–2):122–30.

    Article  PubMed  CAS  Google Scholar 

  • Ishikawa M, Mizukami K, Iwakiri M, Asada T. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiat. 2007;31(6):1177–81.

    Article  CAS  Google Scholar 

  • Lindskog M, Svenningsson P, Pozzi L, et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature. 2002;418(6899):774–8.

    Article  PubMed  CAS  Google Scholar 

  • Mahajan SD, Aalinkeel R, Reynolds JL, et al. Therapeutic targeting of “DARPP-32”: a key signaling molecule in the dopiminergic pathway for the treatment of opiate addiction. Int Rev Neurobiol. 2009;88:199–222.

    Article  PubMed  CAS  Google Scholar 

  • Meyer-Lindenberg A, Straub RE, Lipska BK, et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest. 2007;117(3):672–82.

    Article  PubMed  CAS  Google Scholar 

  • Reis HJ, Rosa DV, Guimaraes MM, et al. Is DARPP-32 a potential therapeutic target? Expert Opin Ther Targets. 2007;11(12):1649–61.

    Article  PubMed  CAS  Google Scholar 

  • Risinger FO, Freeman PA, Greengard P, Fienberg AA. Motivational effects of ethanol in DARPP-32 knock-out mice. J Neurosci. 2001;21(1):340–8.

    PubMed  CAS  Google Scholar 

  • Rosa DV, Souza RP, Souza BR, et al. DARPP-32 expression in rat brain after electroconvulsive stimulation. Brain Res. 2007;1179:35–41.

    Article  PubMed  CAS  Google Scholar 

  • Souza BR, Motta BS, Rosa DV, et al. DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics. Neurochem Res. 2008;33(3):533–8.

    Article  PubMed  CAS  Google Scholar 

  • Souza RP, Soares EC, Rosa DV, et al. Cerebral DARPP-32 expression after methylphenidate administration in young and adult rats. Int J Dev Neurosci. 2009;27(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  • Souza BR, Torres KC, Miranda DM, et al. Lack of effects of typical and atypical antipsychotics in DARPP-32 and NCS-1 levels in PC12 cells overexpressing NCS-1. J Negat Results Biomed. 2010;9:4.

    Article  PubMed  Google Scholar 

  • Svenningsson P, Fienberg AA, Allen PB, et al. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. J Neurochem. 2000;75(1):248–57.

    Article  PubMed  CAS  Google Scholar 

  • Svenningsson P, Nairn AC, Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J. 2005;7(2):E353–60.

    Article  PubMed  CAS  Google Scholar 

  • Svenningsson P, Nishi A, Fisone G, et al. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004;44:269–96.

    Article  PubMed  CAS  Google Scholar 

  • Svenningsson P, Tzavara ET, Carruthers R, et al. Diverse psychotomimetics act through a common signaling pathway. Science. 2003;302(5649):1412–5.

    Article  PubMed  CAS  Google Scholar 

  • Svenningsson P, Tzavara ET, Witkin JM, et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA. 2002;99(5):3182–7.

    Article  PubMed  CAS  Google Scholar 

  • Torres KC, Souza BR, Miranda DM, et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiat. 2009;33(2):214–9.

    Article  CAS  Google Scholar 

  • West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci. 2002;22(1):294–304.

    PubMed  CAS  Google Scholar 

  • Zachariou V, OitMarand M, Allen PB, et al. Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1. Biol Psychiatry. 2002;51(8):612–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INCT de Medicina Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Dr. Daniela V. Rosa & Dr. Luiz Alexandre V. Magno

  2. Department of Cell & Systems Biology, Centre for the Analysis of Genome Evolution and Function, University of Toronto, 25 Harbord Street, M5S 3G5, Toronto, ON, Canada

    Dr. Bruno R. Souza

  3. INCT de Medicina Molecular; Departamento de Saúde Mental, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Dr. Marco A. Romano-Silva

Authors
  1. Dr. Daniela V. Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Luiz Alexandre V. Magno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Bruno R. Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. Marco A. Romano-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco A. Romano-Silva .

Editor information

Editors and Affiliations

  1. Department of Molecular Science and Technology, Ajou University, Suwon, Korea

    Sangdun Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this entry

Cite this entry

Rosa, D.V., Magno, L.A.V., Souza, B.R., Romano-Silva, M.A. (2012). DARPP. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0461-4_557

Download citation

Publish with us

Policies and ethics

Search

Navigation